Wesana Health reports positive treatment results in combining traditional antidepressants with psilocybin-based therapy.
Articles
Revitalist Launches UNIT Initiative Working With Veteran and First Responder Non-Profits Across the United States Creating Nationwide Guidelines
Revitalist Lifestyle and Wellness announces a new initiative focusing on providing access to mental health therapies for veterans and first-responders.
Red Light Holland Successfully Imports Psilocybin iMicrodose Packs into St. Vincent and the Grenadines Under a First-Ever Authorized Import Approval Process by the Country's Bureau of Standards and the Ministry of Health
Red Light Holland announces the first-ever import of psilocybin mushrooms into St. Vincent and the Grenadines.
Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
Awaken receives regulatory approval to begin ketamine-based therapies in its flagship London mental health clinic.
MINDCURE Provides Update on Strategic Review
MINDCURE announces the completion of its strategic review and new cost saving measures.
Ketamine Wellness Centers (KWC) Announces Grand Opening of Reno Clinic
Ketamine Wellness Centers, a subsidiary of Delic Holdings, announces the grand opening of its 13th ketamine clinic.
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
Novamind announces it will most MindMed's Phase IIb clinical trial of LSD-based therapy for generalized anxiety disorder (GAD).
Brain Injury Awareness Month: New Hope With Psychedelic Medicine
Thanks to the advance of psychedelic medicine, "brain injury awareness" is about more than highlighting a problem. It's also about new hope for sufferers.
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
Enveric Bioscience announces the publishing of four PCT applications by the World Intellectual Property Organization.
Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013
Wesana Health reports positive feedback from FDA on pre-IND meeting regarding development of SANA -013 and is anticipating commencing a clinical trial in Q4 2022.
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
Bright Minds Biosciences announced the successful completion of a 28-day toxicology study for BMB-101.
Numinus Expands Natural Psychedelic Research with New Biosecurity License
Numinus announces that its Numinus Bioscience research lab has been approved for a Containment Level 2 (CL2) license from Health Canada.
Red Light Holland and Advocacy Group Psychedelic Medicine Alliance Washington Celebrate the Success of their Collaboration as Washington Legislature Funds Psilocybin Wellness Workgroup
Red Light Holland applauds the decision of Washington State's government to provide $200,000 in funding for psychedelics research.
How Capital Markets Are Fueling Psychedelic Medicine Growth
The psychedelic medicine industry is growing. There was a wave of new psychedelic firms going public, with big names like MindMed and Atai Life Sciences listing on major stock exchanges like the NASDAQ, and increased acceptance of psychedelics by institutional investors.
Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies
Incannex reports a strong clinical response in its trial of a cannabinoid combination product IHL-42X for sleep apnea.